Anti-Mouse CD317 [Clone 927] — Purified in vivo PLATINUM™ Functional Grade

Anti-Mouse CD317 [Clone 927] — Purified in vivo PLATINUM™ Functional Grade

Product No.: C792

[product_table name="All Top" skus="D353"]

- -
- -
Clone
927
Target
CD317
Formats AvailableView All
Product Type
Monoclonal Antibody
Alternate Names
BST2, tetherin, HM1.2 antigen, bone marrow stromal antigen 2, PDCA-1
Isotype
Rat IgG2b κ
Applications
Depletion
,
FA
,
FC
,
ICC
,
IF Microscopy
,
in vivo

- -
- -
Select Product Size
- -
- -

Antibody Details

Product Details

Reactive Species
Mouse
Host Species
Rat
Recommended Isotype Controls
Recommended Dilution Buffer
Immunogen
Mouse plasmacytoid dendritic cells
Product Concentration
≥ 5.0 mg/ml
Endotoxin Level
<0.5 EU/mg as determined by the LAL method
Purity
≥98% monomer by analytical SEC
>95% by SDS Page
Formulation
This monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.
Product Preparation
Functional grade preclinical antibodies are manufactured in an animal free facility using in vitro cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.
Pathogen Testing
To protect mouse colonies from infection by pathogens and to assure that experimental preclinical data is not affected by such pathogens, all of Leinco’s Purified Functional PLATINUM™ antibodies are tested and guaranteed to be negative for all pathogens in the IDEXX IMPACT I Mouse Profile.
Storage and Handling
Functional grade preclinical antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at ≤ -70°C. Avoid Repeated Freeze Thaw Cycles.
Country of Origin
USA
Shipping
Next Day 2-8°C
Applications and Recommended Usage?
Quality Tested by Leinco
FC
Additional Applications Reported In Literature ?
In vivo depletion
immunofluorescence microscopy
functional assay
Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change.

Description

Description

Specificity
Clone 927 activity is directed against murine CD317 (BST2; PDCA-1).
Background
Monoclonal antibody (mAb) 927 recognizes CD317 (BST2; PDCA-1)1. CD317 is a specific marker of IFN-producing cells (IPCs aka plasmacytoid dendritic cells, DC) under naïve conditions. IPCs are early responders to viral infection and direct both the innate and adaptive immune response2,3. CD317 also promotes secretion in IPCs, presumably by sorting proteins between the Golgi apparatus and plasma membrane1. CD317 is located on the cell surface as well as intracellularly in the Golgi apparatus and is associated with lipid rafts.

CD317 is primarily present on the cell surfaces of murine IPCs in naïve mice, where its expression on resting and activated IPCs is independent of IFNs1. However, when stimulated with type I IFNs and IFN-γ, cell surface expression of CD317 is induced on most cell types. When administered in vivo, treatment with mAb 927 abrogates IFN-α secretion by IPCs in response to CpG as well as depletes IPCs ~ 95%, significantly reducing plasma cells.

The 927 clone was generated to overcome barriers to the identification and study of IPCs caused by their scarcity in blood and tissues as well as their complex surface phenotype1. mAb 927 was generated by immunizing Wistar/CRL rats with bone marrow-derived IPCs with either CpG oligodeoxynucleotide 1826 or heat-killed Mycobacteria tuberculosis as adjuvant. Hybridoma lines were created by fusing popliteal lymph nodes with SP2/0 myeloma cells. Supernatants were screened for lines that recognize CD11c+B220+Ly-6c+CD11b-splenocytes. mAb 927 is rat IgG2b isotype.
Antigen Distribution
Murine CD317 is expressed by IFN-producing cells in naïve mouse spleen and by a wide variety of cell lines including T cells, mast cells, B cells, fibroblast cells, and pluripotent embryonal carcinoma cells. Additionally, mice challenged by influenza or other stimuli (CpG, LPS, murine CMV, poly(I:C), and imiquimod) express CD317 in DC and other myeloid cells as well as T cells, B cells, NKT cells, and some NK cells. CD317 is also expressed on CD138+ plasma cells in naïve mice and is upregulated by viral stimulation.
Function
Recently identified antiviral protein that blocks the release of nascent retrovirus or other particles from infected cells.
NCBI Gene Bank ID
Research Area
Immunology

Leinco Antibody Advisor

Powered by AI: AI is experimental and still learning how to provide the best assistance. It may occasionally generate incorrect or incomplete responses. Please do not rely solely on its recommendations when making purchasing decisions or designing experiments.

Clone 927 is a monoclonal antibody commonly used in in vivo mouse studies to specifically deplete plasmacytoid dendritic cells (pDCs) and to block interferon-alpha (IFN-?) secretion by pDCs and other IFN-producing cells. Its target is murine CD317 (also known as BST2 or PDCA-1), a cell surface molecule predominantly expressed on these cell types.

Key uses and details:

  • pDC Depletion: When administered in vivo, clone 927 effectively depletes pDCs by as much as ~95% in mice, which allows researchers to study the biological roles and downstream effects of these cells in immune responses.
  • Functional Blockade: Administration of 927 also abrogates IFN-? secretion in response to stimuli such as CpG oligodeoxynucleotides, blocking a major functional output of pDCs and related IFN-producing cells.
  • Experimental Applications: Clone 927 is utilized in experimental settings where selective removal or inactivation of pDCs or IFN-producing cells is desired, including studies of antiviral immunity, autoimmunity, and inflammation.
  • Antigen Distribution: CD317 expression in the mouse is mostly restricted to IFN-producing cells and pDCs under normal conditions, but can be upregulated in other immune cell types upon stimulation (e.g. with IFNs, virus exposure, TLR ligands).

In summary, in vivo mouse studies use clone 927 to deplete pDCs and block type I interferon production, enabling mechanistic studies of immune cell function, especially relating to the innate response to pathogens and immunomodulation.

The correct storage temperature for sterile packaged clone 927 (anti-mouse CD317 monoclonal antibody) is 2–8°C when stored as received in sterile form for up to one month. For longer-term storage, aliquot the product aseptically without diluting and store at ? –70°C. Avoid repeated freeze-thaw cycles to preserve antibody integrity.

  • Short-term (up to 1 month): 2–8°C
  • Long-term: ? –70°C (after aliquoting, do not dilute)
  • The antibody should be stored undiluted.
  • Always avoid repeated freeze/thaw cycles.

These guidelines apply specifically to sterile, functional-grade clone 927 antibody, as per the manufacturer's recommendations. For any changes in storage or handling practices, consult the lot-specific datasheet, as they may be periodically updated.

Some of the most commonly used antibodies or proteins with clone 927 in the literature include surface markers and lineage-defining proteins typical of immune and dendritic cell profiling, as well as markers for specific cell depletion and functional assays.

Key antibodies or proteins that are often used in combination with 927 include:

  • CD11c: A classical marker for dendritic cells; frequently used with 927 to help define plasmacytoid dendritic cell (pDC) populations or distinguish them from conventional DCs.
  • B220: Also known as CD45R, this marker is commonly used to identify B cells and plasmacytoid dendritic cells; often paired with 927 in immunophenotyping panels for murine studies.
  • Ly-6C: Utilized as a marker for distinguishing pDCs as part of multicolor flow cytometry panels.
  • CD11b: Serves as an exclusion marker (pDCs are CD11b^? in mice); used to refine gating strategies in combination with 927.

In the generation and validation of clone 927, hybridomas were screened against cells that were CD11c^+ B220^+ Ly-6C^+ CD11b^? (splenocytes) to ensure specificity for murine CD317/BST2 (PDCA-1), which is the antigen recognized by 927.

In addition, 927 itself is commonly used for:

  • Depletion of plasmacytoid dendritic cells in vivo
  • Functional blockade of CD317/BST2
  • Immunofluorescence and immunohistochemistry, frequently alongside the above markers

These antibody combinations and panels are widely reported in the immunology literature to characterize or experimentally deplete pDC populations and to study immune responses in various mouse models.

Key findings from scientific literature that cite "clone 927" primarily relate to its use as a monoclonal antibody targeting mouse CD317 (also known as BST2 or PDCA-1) and to its utility in the identification, depletion, and functional study of interferon-producing cells (IPCs), especially plasmacytoid dendritic cells (pDCs).

Key Findings:

  • Clone 927 was developed to address difficulties in identifying and studying IPCs due to their rarity and complex phenotype in murine tissues.
  • The antibody specifically recognizes CD317, which serves as a marker for IPCs (plasmacytoid dendritic cells) in mice under naïve (non-inflamed) conditions.
  • CD317 expression on IPCs is typically independent of interferons (IFNs), but type I IFNs and IFN-? can induce CD317 on many other cell types.
  • In vivo administration of clone 927:
    • Ablates IFN-? secretion by IPCs in response to CpG stimulation.
    • Depletes IPCs by approximately 95% in treated mice, which also leads to a significant reduction in plasma cells.
  • CD317 is found both on the cell surface and within the Golgi apparatus of IPCs, participating in protein sorting and the immune response to viral stimulation.
  • Clone 927 (rat IgG2b) was generated by immunizing rats with bone marrow-derived IPCs, then screening for antibodies recognizing CD11c+B220+Ly-6C+CD11b– splenocytes.

Broader Implications:

  • Clone 927 has been instrumental in research exploring the role of IPCs/pDCs in innate and adaptive immune responses, and in experiments requiring the depletion or tracking of these cells.
  • Its use allows for the study of pDC functions, depletion effects, and surface marker expression dynamics during infection, inflammation, or immune modulation.

Alternative "927" Usage:

  • DJ-927, unrelated to clone 927/CD317, is a novel oral taxane drug tested for cancer therapy, notable for overcoming P-glycoprotein-mediated drug resistance. This is a distinct scientific context and not directly related to clone 927 antibody research.

In summary, clone 927 citations in scientific papers consistently highlight its pivotal role as a tool for identifying, depleting, and functionally analyzing mouse IPCs/pDCs, thus facilitating research in immunology and cell biology.

References & Citations

1. Blasius AL, Giurisato E, Cella M, et al. J Immunol. 177(5):3260-3265. 2006.
2. Colonna M, Trinchieri G, Liu YJ. Nat Immunol. 5(12):1219-1226. 2004.
3. Liu YJ. Annu Rev Immunol. 23:275-306. 2005.
4. Yun TJ, Lee JS, Machmach K, et al. Cell Metab. 23(5):852-866. 2016.
5. Toivonen R, Kong L, Rasool O, et al. J Immunol. 196(11):4750-4759. 2016.
6. Moniz RJ, Chan AM, Gordon LK, et al. FEMS Immunol Med Microbiol. 58(3):397-404. 2010.
7. Rajagopal D, Paturel C, Morel Y, et al. Blood. 115(10):1949-1957. 2010.
8. Nash WT, Gillespie AL, Brown MG. Front Immunol. 8:251. 2017.
9. Bradley KC, Finsterbusch K, Schnepf D, et al. Cell Rep. 28(1):245-256.e4. 2019.
10. Schliemann C, Roesli C, Kamada H, et al. Blood. 115(3):736-744. 2010.
Depletion
FA
Flow Cytometry
ICC
IF Microscopy
in vivo Protocol

Certificate of Analysis

Formats Available

- -
- -
Disclaimer AlertProducts are for research use only. Not for use in diagnostic or therapeutic procedures.